A US appeals court has blocked Novartis from selling the first biosimilar to be approved in the United States. When Sandoz, a Novartis company, acquired FDA approval for Zarxio (filgrastim-sndz) a ...
A judge for the US Court of Appeals for the Federal Circuit declined an Amgen motion for a temporary injunction that would have prevented the launch of the first biosimilar in the US—Novartis’s Zarxio ...
A year ago, providers, plans and pharmacy benefit managers thought they were on the brink of a new era of competitive drug prices. The federal approval of the first biosimilar for sale in the U.S. was ...
zarxio The FDA has approved a supplemental Biologics License Application (sBLA) for Zarxio (filgrastim-sndz; Sandoz) to update the Warnings and Precautions section of the drug label. The Food and Drug ...
The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications. The Food and Drug Administration has ...
The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015 - Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available ...
Novartis ' NVS generic arm, Sandoz, has announced the launch of Zarxio (filgrastim-sndz) in the U.S. Zarxio, the biosimilar version of Amgen's AMGN blockbuster drug, Neupogen, became the first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results